Healthcare Industry News: nanoparticle
News Release - April 2, 2013
BIND Therapeutics Appoints Gregory I. Berk, M.D. as Chief Medical Officer
CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, today announced the appointment of Gregory I. Berk, M.D. as Chief Medical Officer, effective immediately. Dr. Berk will be responsible for leading the Company's global clinical development strategy and clinical operations.“As an oncologist with more than 20 years of global industry and academic experience, Greg’s expertise is proving invaluable as we aggressively move forward with our targeted and programmable therapeutic pipeline, including BIND-014, our lead Accurin for the treatment of solid tumors which is poised to enter Phase 2 clinical trials in the coming months,” said Scott Minick, President and Chief Executive Officer of BIND Therapeutics. “Greg’s clinical vision and proven leadership, as well as his extensive medical and research experience, will strengthen our clinical development efforts and support the future progress of our product pipeline.”
“BIND’s targeted and programmable nanoparticle technology is a paradigm shift in oncology therapeutics and has the potential to significantly improve patient outcomes,” commented Dr. Berk. “I am excited to be joining BIND, particularly at this stage, as we prepare to advance a pipeline of novel Accurins, including BIND-014 for cancer, which has demonstrated very strong early clinical results to date that show how BIND’s technology can create therapies with new levels of selectivity and targeting.”
Dr. Berk is an oncology veteran with more than 20 years of industry and academic experience. Prior to joining BIND, Dr. Berk served as Chief Medical Officer of Intellikine, a clinical stage company developing small molecule drugs targeting signal transduction networks, which was acquired by Takeda Pharmaceutical Company Limited. Dr. Berk was previously Senior Vice President of Global Clinical Development at Abraxis BioScience, where he was responsible for the company’s overall clinical strategy, including efforts to expand the indications for their lead clinical program (Abraxane®), as well as oversee the clinical development of their entire pipeline. Dr. Berk also served on the integration leadership team during the Celgene acquisition of Abraxis in 2010. Dr. Berk obtained his medical degree from Case Western Reserve University, and completed his internship, residency, and fellowship in internal medicine, hematology, and medical oncology, at the Weill Medical College of Cornell University and New York Presbyterian Hospital, where he also served as a faculty member from 1989-2004. During this time Dr. Berk served as an investigator on several industry-sponsored and cooperative group clinical trials, including the pivotal trials for Gleevec® and Avastin®.
About BIND Therapeutics
BIND Therapeutics is a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM. BIND’s Medicinal NanoengineeringTM platform enables the design, engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites, dramatically enhancing efficacy while minimizing toxicities.
BIND is developing a pipeline of novel Accurins that hold extraordinary potential to become best-in-class drugs and improve patient outcomes in the areas of oncology, inflammatory diseases and cardiovascular disorders. BIND's lead product candidate, BIND-014, is currently in Phase 1 clinical testing in cancer patients and is designed to selectively target a surface protein upregulated in a broad range of solid tumors. BIND also develops Accurins in collaboration with pharmaceutical and biotechnology partners to enable promising pipeline candidates to achieve their full potential and to utilize selective targeting to transform the performance of important existing drug products.
BIND is backed by leading investors, Polaris Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments, EndeavourVision and Rusnano. BIND was founded on proprietary technology from the laboratories of two leaders in the field of nanomedicine, Professors Robert Langer, David H. Koch Institute Professor of the Massachusetts Institute of Technology (MIT) and Omid Farokhzad, Associate Professor of Harvard Medical School. For more information, please visit the company's web site at www.bindbio.com.
Source: BIND Therapeutics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
